Repository logo
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    Have you forgotten your password?
Repository logoRepository logo
  • Communities & Collections
  • All Contents
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Serdaroglu, S"

Now showing 1 - 3 of 3
Results Per Page
Sort Options
  • No Thumbnail Available
    Item
    Quality of life, anxiety and depression in patients with androgenetic alopecia
    Bilaç, C; Kutlubay, Z; Öztürkcan, S; Serdaroglu, S; Sahin, MT; Yasar, A; Dinç, G
    Background: Androgenetic alopecia (AGA) is a common form of hair loss, which can result in body image disorder and negative social feelings. Aim: The aim of this study was to evaluate the quality of life (QoL) and the risk of anxiety and depression in AGA patients. Method: Sociodemographic data of the patients and clinical severity of the disease were recorded. The QoL score of patient and controls was evaluated with DLQI and SF-36 instruments, their anxiety and depression risks were evaluated with HAD (HAD-A and HAD-D) instruments. Results: Sixty-eight patients with AGA were included in our study. Young male AGA patients' quality of life levels were found to be low according to role limitations due to emotional problems, emotional wellbeing and emotional scores of SF-36 scale and younger female AGA patients quality of life levels were also found to be low according to role limitations due to emotional problems, and emotional scores of SF-36 scale. The DLQI scores of patients of both sex were found to be significantly higher compared to control group. According to anxiety and depression risk assessment with HAD scale, it was found that 28.6% and 73.5% of patients were prone to suffer from anxiety and depression respectively. Conclusion: Apart from managing alopecia, practitioners should be aware of the possible psychosocial distress of AGA patients and manage accordingly.
  • No Thumbnail Available
    Item
    Relationship of psoriatic arthritis with nail and scalp involvement in Turkish psoriasis patients: Multicentered cross-sectional study
    Askin, O; Engin, B; Ozdede, A; Kartal, SP; Ugurlu, S; Akbulut, TO; Ekinci, AP; Aydogdu, IH; Ozden, MG; Kok, H; Dogan, S; Ozturkcan, S; Borlu, M; Baskan, EB; Yilmaz, N; Ak, T; Topkarci, Z; Serdaroglu, S
    Psoriasis is a common multisystem inflammatory disease, and arthritis is an essential component of the disorder, requiring early diagnosis and prompt treatment for successful management. In this study, we aimed to investigate the relationship between nail and scalp involvement and other covariates with psoriatic arthritis (PsA). This cross-sectional study, conducted from June 2021 through December 2021, included 763 patients from 11 different centers in Turkey. The severity of involvement was evaluated using psoriasis area severity index (PASI), nail psoriasis severity index (NAPSI), and psoriasis scalp severity index (PSSI) scores. Predictors for PsA were evaluated using univariate and multivariate logistic regression models. PsA (n = 155, 21.5%) was significantly more common in patients having a family history of psoriasis (43.2% vs 30.9%, P = .004), nail involvement (68.4% vs 52.3%, P < .001), and coexistence of nail and scalp involvement (53.7% vs 39.6%, P = .002). Furthermore, patients with PsA had considerably higher PASI (7 vs 5.6, P = .006), NAPSI (5 vs 2, P < .001), and PSSI scores (7 vs 4, P = .002) and longer disease duration (months) (126 vs 108, P = .009). In multivariate analysis, female gender [OR: 3.01, 95% CI (1.861-4.880), P < .001], nail involvement [OR: 2.06, 95% CI (1.293-3.302), P = .002)], and body mass index (BMI) [OR: 1.06, 95% CI (1.017-1.100), P = .005] were identified as independent predictors for PsA. Female gender, nail involvement, and high BMI are significant predictors for PsA and warrant detailed rheumatological assessment. Notably, being female is the strongest predictor of increased risk of PsA in our survey. Scalp involvement appears not to be associated with PsA. Also, the presence of PsA seems related to a more severe skin involvement phenotype.
  • No Thumbnail Available
    Item
    Atopic dermatitis diagnosis and treatment consensus report
    Atakan, N; Yalçin, B; Özkaya, E; Küçük, ÖS; Öztürkcan, S; Salman, A; Borlu, M; Sentürk, N; Akman-Karakas, A; Serdaroglu, S
    Atopic dermatitis (AD) is a chronic, itchy, and recurrent inflammatory skin disease. AD, which is known as a childhood disease because of its common occurrence, is also an important health problem in adults. With increasing prevalence rates throughout each year, particularly in developed countries, AD has a heterogeneous clinical presentation that varies with age and different degrees of severity. The treatment includes the use of topical or systemic agents after identifying the needs of the patients. Especially, the identification of molecules responsible for pathogenesis recently has allowed the development of tailored treatments. With a better understanding of both the disease and the economic burden of AD recently, studies have gained momentum on diagnosis, treatment, and quality of life. Guidelines and consensus reports addressing diagnostic and therapeutic approaches have been published in our country, too, in parallel to publications in various countries. In this age of rapid information sharing, all kinds of information need to be updated frequently and become further useful. For this purpose, it is planned to develop a current consensus guideline under the leadership of the Dermatoimmunology and Allergy Association, with the contributions of the Cosmetology and the Dermatology Academy Association, Kayseri Dermatology and the Venereal Diseases Association, and Manisa Dermatology and the Venereal Diseases Association, and through the participation of faculty members experienced in the diagnosis and treatment of AD. The topics and the authors were chosen in December 2020. All Medline data published in the years between 1980 and 2021, current AD diagnosis and treatment guidelines, meta-analytical studies, and expert opinions and experiences were reviewed, and section drafts were developed. Literature data and section drafts were assessed and discussed during a meeting held in March 2021 with the participation of all authors. Then, the sections were finalized via e-mail correspondences and submitted as a final consensus report.

Manisa Celal Bayar University copyright © 2002-2025 LYRASIS

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback